News

Hikma gets large U.S. plant in Boehringer Ingelheim generics deal

Last year when Hikma bought Boehringer Ingelheim's Ben Venue injectable business, it decided not to reopen its long-troubled Bedford, OH, plant. But with a $2.65 billion deal announced today for Boehringer's Roxane generics business, it gets a U.S. manufacturing plant that it says it likes the looks of.

EU ban on more than 700 drugs set for Aug. 21

The European Union will impose a ban starting Aug. 21 on more than 700 drugs that were bioequivalency tested by India's GVK BioSciences after inspectors raised questions about its procedures.

Androxy returns to market after 9-month lapse

Upsher-Smith had to quit shipping fluoxymesterone tablets last fall when its supplier quit making the API for Androxy. The problem was that Upsher-Smith is the only supplier in the U.S. for the drug, which is used to treat breast cancer in women and low testosterone in men. Now Upsher-Smith says Androxy is back.

Teva expands recall of cancer drug Adrucil

Teva Pharmaceutical Industries voluntarily recalled 8 lots of a cancer drug a couple of months ago after rubber particles were found in some containers. Now the generics maker says the problem is more widespread than it first thought and more units will need to be retrieved.

Avista Pharma snaps up NC manufacturing facility from rival Scynexis

Avista Pharma Solutions has snapped up the manufacturing, development and animal health services business from rival Scynexis in a move designed to bulk up its capacity and garner a larger share of the growing market.

Hospira recall of ketorolac now close to 40 million vials

After recalling 18 million vials last January of a painkiller commonly used in surgery, sterile injectables maker Hospira indicated that it was on top of the problem. But the company now says new manufacturing issues have cropped up that have led it to recall more than 20.7 million more vials of ketorolac, a drug on the FDA shortage list.

Sun may only get 3 of Ranbaxy's 4 banned plants ready for U.S. market

Ranbaxy Laboratories, which Sun Pharmaceutical recently acquired for $4 billion, has four plants in India that once produced products for the U.S. market. All four were banned by the FDA over the last 5 years for manufacturing and drug testing issues. But Sun may now only intend to spend the time and money to get three of them back to FDA standards.

Capsugel expanding plant in Scotland

Capsule maker and drug formulation specialist Capsugel has been beefing up its production capacities around the globe and will now turn its attention to a plant in Scotland that it picked up in 2013.

Lonza revenue growth can't protect Swiss plant from deeper job cuts

Swiss ingredient maker Lonza says its expansion in biologics manufacturing, including a new plant in the U.S., continues to build momentum and helped it realize revenue growth in the first half of the year. But costs at its massive operations in Visp, Switzerland, continue to be a drag and will result in the loss of more jobs there.

Patheon, DPx unload chemical operations to tighten focus on pharma

Patheon and its parent, DPx, have been on a buying and expansion binge since the company was created last year, grabbing up smaller CMOs to build out both capabilities and capacity. With an IPO in the works, more deals may be coming but the CDMO has ended up with operations that don't fit its model and is shedding those along the way, including two deals this week.

Lupin gets first U.S. manufacturing base with buyout of GAVIS

India's Lupin has landed its first manufacturing site in the U.S. with an $880 million deal to buy a small generics maker in New Jersey that specializes in niche products including dermatology controlled substances.

Sandoz gives Novartis a boost, but 3 plants still get the boot

Novartis's generics business Sandoz provided the key bright spot in an otherwise tough earnings report for the Swiss pharma, with revenues up 10%. But the starring performance did not keep the manufacturing side of Sandoz from getting spanked, with three of its plants now targeted for closing.

Amgen's Colorado plant hits the market for $85M

Amgen's manufacturing and R&D sites in Colorado are officially on the block and the company is hoping another drugmaker will be interested in buying them.

Biogen gets all of North Carolina site from Eisai as part of manufacturing build-out

When Biogen announced a few weeks ago that it intends to build a $1 billion new biologics plant in Switzerland, officials said the Cambridge, MA-based company had more manufacturing expansion up its sleeve. At least part of the great reveal was made last week when Japanese partner Eisai said it was turning over manufacturing operations in North Carolina to Biogen.

Valeant gets manufacturing in Middle East with deal for Amoun

With its $800 million deal for Amoun Pharmaceutical, Valeant picks up what the Egyptian drugmaker says is one of the largest and most up-to-date pharmaceutical facilities in Africa and the Middle East.

Baxter IDs particulate in recalled saline as insects

With the completion of a spinoff July 1, Baxter International let go of most of its drug operations go with Baxalta while keeping its dialysis equipment, IV pumps and solutions, and injectable drugs and intravenous nutrition. In that category falls saline solution, and Baxter is again having to recall some of that; in this case, two lots because a customer discovered particulate that turned out to be insects.

AMRI picks up Spanish drugmaker in $174M deal

Albany, NY-based contract manufacturer AMRI has continued its buying spree for more and more diverse manufacturing capacity, and the deals are getting larger. Its latest is a $174 million deal for a drugmaker in Spain that makes specialty APIs and sterile injected drugs.

FDA bars from industry man convicted of selling foreign-made drugs

Talib Khan is already doing time in federal facility in Philadelphia, but the FDA has let him know that once he is out, he is barred from ever working for any company that sells FDA-approved drugs.

GSK ramps up flu vax production after problems last year

GlaxoSmithKline has begun shipping its flu vaccine for the coming season after facing a string of issues last year that included receiving a warning letter for a flu vax plant and culminated with it pulling about 1.7 million doses of a vaccine from the market just a couple of months ago. But the British drugmaker says it is ready for this year and expects to ship up to 38 million doses of two flu vaccines, both formulated to protect against four strains of the virus.

American Health Packaging pulls thousands of Wockhardt-made products from the market

The burden of recalling products manufactured at Wockhardt's two plants in India currently under FDA bans has fallen in part to American Health Packaging, a subsidiary of AmerisourceBergen, which has issued more than a dozen recalls of 6 products in different doses.